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Abstract
Background: Chitosan, a polymer derived from chitin, has been used for nasal drug delivery
because of its biocompatibility, biodegradability and bioadhesiveness. Theophylline is a drug that
reduces the inflammatory effects of allergic asthma but is difficult to administer at an appropriate
dosage without causing adverse side effects. It was hypothesized that adsorption of theophylline to
chitosan nanoparticles modified by the addition of thiol groups would improve theophylline
absorption by the bronchial epithelium and enhance its anti-inflammatory effects.
Objectives: We sought to develop an improved drug-delivery matrix for theophylline based on
thiolated chitosan, and to investigate whether thiolated chitosan nanoparticles (TCNs) can enhance
theophylline's capacity to alleviate allergic asthma.
Methods: A mouse model of allergic asthma was used to test the effects of theophylline in vivo.
B A L B / c  m i c e  w e r e  s e n s i t i z e d  t o  o v a l b u m i n (OVA) and OVA-challenged to produce an
inflammatory allergic condition. They were then treated intranasally with theophylline alone,
chitosan nanoparticles alone or theophylline adsorbed to TCNs. The effects of theophylline on
cellular infiltration in bronchoalveolar lavage (BAL) fluid, histopathology of lung sections, and
apoptosis of lung cells were investigated to determine the effectiveness of TCNs as a drug-delivery
vehicle for theophylline.
Results: Theophylline alone exerts a moderate anti-inflammatory effect, as evidenced by the
decrease in eosinophils in BAL fluid, the reduction of bronchial damage, inhibition of mucus
hypersecretion and increased apoptosis of lung cells. The effects of theophylline were significantly
enhanced when the drug was delivered by TCNs.
Conclusion:  Intranasal delivery of theophylline complexed with TCNs augmented the anti-
inflammatory effects of the drug compared to theophylline administered alone in a mouse model
of allergic asthma. The beneficial effects of theophylline in treating asthma may be enhanced
through the use of this novel drug delivery system.
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Background
Asthma is a chronic inflammatory disease of the airway
characterized by the infiltration of eosinophils, epithelial
hyperplasia leading to hypersecretion of mucus and the
presence of airway hyperresponsiveness (AHR) to a vari-
ety of stimuli [1,2]. Theophylline had been used world-
wide for the treatment of asthma for several decades, but
its use has recently declined owing to the increased use of
inhaled glucocorticoids. Theophylline's side effects, such
as nausea, headache and cardiac arrhythmias, at the dose
necessary to achieve bronchodilation (plasma levels of 10
to 20 mg/L) in asthma also limit its use [1,3]. In spite of
these drawbacks, theophylline remains a widely pre-
scribed anti-asthmatic agent [4-6].
In addition, theophylline has been reported to suppress
the activation of inflammatory cells, such as neutrophils
and eosinophils at concentrations lower than what is
required for bronchodilation [3,7,8]. Recent clinical and
experimental research showed that theophylline at
plasma levels of <10 mg/L still possesses anti-inflamma-
tory and immunomodulatory properties, which may per-
mit its use in the long-term treatment of chronic
obstructive pulmonary inflammation [9,10]. The inci-
dence of adverse side effects is minimized at this dose [1].
Chitosan, a linear polysaccharide derived from chitin
obtained from crustacean shells, has emerged as a useful
drug delivery matrix because of it polycationic nature, bio-
degradability, biocompatibility, mucoadhesiveness and
ease of physical and chemical modification [11]. The
interaction between cationic amino groups on chitosan
and anionic moieties such as sialic and sulfonic acids on
the mucus layer is responsible for its mucoadhesiveness
[12]. In addition, chitosan enhances epithelial permeabil-
ity through the opening of tight junctions between epithe-
lial cells [13]. Recently, it was reported that the covalent
attachment of thiol groups to polymers greatly increases
their mucoadhesiveness and permeation properties with-
out affecting biodegradability [12,14].
In this study, we hypothesized that the absorption of the-
ophylline through bronchial mucosa could be enhanced
by administration with thiolated chitosan nanoparticles
(TCNs) because of their greater mucoadhesiveness and
permeability properties. The anti-inflammatory effects of
theophylline were measured in BALB/c mice that had
been made allergic to ovalbumin. Histopathology of lung
tissue after OVA challenge, eosinophilia in bronchoalveo-
lar lavage fluid, levels of mucin production and apoptosis
of lung cells were examined to evaluate the effects of the-
ophylline.
Materials and methods
Materials
Chitosan (33 kDa) was obtained from TaeHoon Bio. Co
(Korea) and used as received. The viscosity and degree of
deacetylation as determined by the supplier were 2.8 cps
(0.5% solution in 0.5% acetic acid at 20°C) and 90%,
respectively. Thioglycolic acid, sodium tripolyphosphate,
theophylline and mucin type I-S (9–17% sialic acid) and
III (~1% sialic acid) were purchased from Sigma-Aldrich,
USA, and used without further purification.
Synthesis of thiolated chitosan
The chemical modification of chitosan was performed as
previously described [15,16]. Chitosan (500 mg) was dis-
solved in 50 mL of 1.0% acetic acid. In order to facilitate
reaction with thioglycolic acid (TGA), 100 mg of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDAC) was added to the chitosan solution. After EDAC
was dissolved, 30 mL of TGA was added and the pH was
adjusted to 5.0 with 3 N NaOH. The reaction mixture was
stirred and left for 3 h at room temperature. To eliminate
the unbound TGA and to isolate the polymer conjugates,
the reaction mixture was dialyzed against 5 mM HCl five
times (molecular weight cut-off 10 kDa) over a period of
3 days in the dark, then two times against 5 mM HCl con-
taining 1.0% NaCl to reduce ionic interactions between
the cationic polymer and the anionic sulfhydryl com-
pound.
Preparation and characterization of chitosan 
nanoparticles
Chitosan suspensions of 0.2% (w/v) were prepared in 1%
acetic acid. Sodium tripolyphosphate (TPP, 1.0%) was
added dropwise to 6 ml of chitosan with stirring, followed
by sonication with a Dismembrator (Fisher Scientific) for
10 sec at a power setting of 3 watts. The resulting chitosan
particle suspension was centrifuged at 10,000 × g for 10
min. The pelleted particles were resuspended in deionized
water with 10 sec sonication and lyophilized. The mean
size and zeta potential of the chitosan nanoparticles were
determined by photon correlation spectroscopy using a
ZetaPlus particle analyzer (Brookhaven Instrument Corp.,
Holtsville, NY, USA).
Adsorption of mucin by chitosan nanoparticles and mucin 
assay
Mucoadhesiveness was calculated as the amount of mucin
adsorbed by 2 mg of chitosan nanoparticles in a certain
time period. Chitosan nanoparticle suspensions (4 mg/
mL) were mixed with type I-S or type III mucin solutions
(0.5 and 1 mg/mL), vortexed, and incubated at 37°C for
1, 6, 12 and 18 h. After adsorption, the suspensions were
centrifuged at 10,000 × g for 10 min and free mucin was
measured in the supernatant by a colorimetric method
using periodic acid/Schiff (PAS) staining [17]. Schiff rea-Respiratory Research 2006, 7:112 http://respiratory-research.com/content/7/1/112
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gent was prepared by diluting pararosaniline solution (40
g/L in 2 M HCl, Sigma) with water to give a final concen-
tration of 1.0%. Sodium bisulfite (80 mg) was added to 5
mL of Schiff reagent and the resultant solution was incu-
bated at 37°C until it became colorless or pale yellow.
Periodic acid solution was freshly prepared by adding 10
µL of 50% periodic acid to 7 mL of 7% acetic acid. Super-
natants were mixed with 100 µL of dilute periodic acid
and incubated for 2 h at 37°C. Then, 100 µL of Schiff rea-
gent was added at room temperature, and after 30 min the
absorbance was measured at 560 nm. The amount of
mucin adsorbed by the chitosan nanoparticles was deter-
mined by subtracting the concentration of mucin in solu-
tion after adsorption from that before. Mucin standards
(0.1, 0.25 and 0.5 mg/mL) were measured by the same
procedure and a standard calibration curve was prepared.
Nasal delivery of theophylline
BALB/c mice (n = 4) were sensitized by i.p. injection of 50
µg ovalbumin (OVA, Sigma Grade V,) precipitated with
alum (Imject, Pierce) on day 1. On day 8 and 14 mice
were challenged intranasally with 50 µg of OVA. Theo-
phylline (30 mM) was added to the chitosan nanoparticle
suspension (4 mg/mL) and allowed to adsorb to the nan-
oparticles for 12 h at room temperature. Mice were given
50 µL of theophylline with or without chitosan nanopar-
ticles intranasally on days 15, 16 and 17. Control mice
were given PBS only.
Determination of eosinophil number in bronchoalveolar 
lavage (BAL) fluid
Mice were euthanized on day 22 and lungs were lavaged
with 500 µL of PBS introduced through the trachea. BAL
fluid was centrifuged at 300 × g for 5 min, rinsed and cells
resuspended with PBS. Aliquots of the cell suspension
were applied to slides by Cytospin (Shandon Scientific) at
500 × g for 5 min allowed to air dry and stained with mod-
ified Wright's stain (Hema-3, Fisher Scientific). The eosi-
nophils were determined morphologically and a
minimum of 200 cells per slide were counted under the
microscope.
Lung histology, mucin production and apoptosis assay
Mice were euthanized and their lungs were perfused with
PBS, removed and fixed in 4% buffered formalin. Lungs
were embedded in paraffin, sectioned and stained with
hematoxylin and eosin. A semi-quantitative microscopic
evaluation of inflammatory cells in the entire lung section
was done by persons blinded to the type of treatment.
Inflammatory infiltrates were assessed morphologically
for location, numbers and cell types [18,19]. Epithelial
changes were scored as: 0 = no change, 1 = increased epi-
thelial cell cytoplasm without desquamation, 2 = epithe-
lial desquamation without bronchial exudates composed
of inflammatory cells, 3 = bronchial exudates composed
of desquamated epithelial cells and inflammatory cells.
For peribronchovascular infiltrates: 0 = no infiltrate, 1 =
infiltrate up to 4 cells thick in most vessels, 2 = infiltrate
from five to seven cells thick in most vessels, 3 = infiltrate
greater than 7 cells thick in most vessels. For interstitial-
alveolar cell infiltrates: 0 = no infiltrate, 1 = mild general-
ized increase in cell mass of the alveolar septa without
thickening of the septa or significant airspace consolida-
tion, 2 = dense septal mononuclear infiltrates with thick-
ening of septa, 3 = significant alveolar consolidation in
addition to interstitial inflammation.
Goblet cells were identified using a monoclonal antibody
to the marker protein mucin 5AC (MUC5AC, Lab Vision
Co) visualized immunohistochemically. The presence of
apoptotic cells was determined by examining sections
using the TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end-labeling) assay. Lung sections from paraf-
fin blocks were dewaxed in xylene, rehydrated to PBS and
fixed with 4% paraformaldehyde for 15 min at room tem-
perature. Sections were washed three times in PBS, perme-
ablized for 15 min with 0.1% Triton X-100 and incubated
with the TUNEL reagent at 37°C for 1 h. The reaction was
terminated by rinsing slides once with 2× SSC and three
times in PBS. The lung sections were examined under a
fluorescent microscope and photographed.
Statistical analysis
Pairs of groups were compared by Student's t test. Differ-
ences between groups were considered significant at p <
0.05. Values for all measurements are expressed as means
± SD.
Results
Characterization of thiolated chitosan nanoparticles
Lyophilized thiolated chitosan (chitosan-thioglycolic acid
conjugates, Fig. 1) is a fibrous white powder easily soluble
in water. The degree of thiolation was determined by
reacting the thiol groups with Ellman's reagent (5,5'-
dithiobis(2-nitrobenzoic acid) and reading the absorb-
ance at 412 nm spectrophotometrically. The content of
thiol groups on thiolated chitosan was found to be 17–30
µM/g. Unmodified and thiolated chitosan nanoparticles
prepared by ionic crosslinking with sodium tripolyphos-
phate have a diameter of 220 ± 23 nm. The zeta potential
is a measure of the charge density on particles and can
affect their capacity for aggregation and interaction with
charged surfaces such as cells or membranes. Because of
its amino groups, unmodified chitosan has a net positive
charge and zeta potential of 22.7 ± 4 mV. Thiolation
reduces the charge somewhat so that TCNs have a zeta
potential of 15.3 ± 2 mV.Respiratory Research 2006, 7:112 http://respiratory-research.com/content/7/1/112
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Mucoadhesiveness of chitosan nanoparticles
Mucin adsorption by TCNs was measured as a way to test
their ability to bind to the mucosal surfaces of the body
(mucoadhesiveness). Mucin, a glycoprotein, is the major
component of the mucus that coats the cells lining the sur-
faces of the respiratory, digestive and urogenital tracts
[20]. Mucoadhesiveness was calculated as the amount of
mucin adsorbed by 2 mg of chitosan nanoparticles in a
Chemical structure of chitosan-thioglycolic acid conjugate (A) and transmission electron micrograph of chitosan nanoparticles  following ionic crosslinking (B) Figure 1
Chemical structure of chitosan-thioglycolic acid conjugate (A) and transmission electron micrograph of chitosan nanoparticles 
following ionic crosslinking (B). Adsorption kinetics of mucin I-S with unmodified and thiolated chitosan nanoparticles (C). 
The value of mucin adsorbed represents the amount of mucin per 2 mg of chitosan nanoparticles. The experiments were 
repeated twice and results are expressed as mean ± S.D (**P < 0.01, *P < 0.05 relative to 1 h).
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certain time period. Unmodified chitosan nanoparticles
adsorbed a larger amount of mucin I-S and mucin III,
compared to thiolated chitosan nanoparticles after 1 h
incubation (data not shown). The amount of mucin
adsorbed increased with mucin concentration and per-
centage of sialic acid residues. Both unmodified and thi-
olated chitosan nanoparticles bound more mucin type I-S
(containing 12% sialic acid) than mucin III (containing
1% sialic acid). Unmodified chitosan nanoparticles
reached adsorption equilibrium at about 1 h at 37°C. In
contrast, TCNs exhibited a more gradual increase in
mucin I-S adsorption and greater binding at 12 h than
unmodified chitosan (Fig. 1c).
In vivo effectiveness of thiolated chitosan delivery of 
theophylline: treatment reduces the number of eosinophils 
in bronchoalveolar lavage (BAL) fluid
The hypothesis of this study was that the absorption of
theophylline by the bronchial epithelium and its pharma-
ceutical action can be enhanced by delivering theophyl-
line as a complex with TCNs. To test this, mice allergic to
ovalbumin (OVA) were challenged with OVA and then
given theophylline or theophylline complexed with chi-
tosan nanoparticles according to the protocol in Fig. 2a.
Eosinophils are known to migrate to the site of an allergic
reaction and to modulate the allergic inflammatory
response [21]. Fig. 2b shows the effect of theophylline
delivery on the percentage of eosinophils in BAL fluid.
Administration of OVA increased the number of eosi-
nophils in the airway at the subepithelial region beneath
the basement membrane compared to unchallenged con-
trols. The percentage of eosinophils in the BAL fluid was
significantly reduced in the group treated with theophyl-
line plus TCNs compared to untreated mice, or mice given
unmodified chitosan, theophylline or theophylline plus
unmodified chitosan.
Thiolated chitosan nanoparticles (TCNs) enhance anti-
inflammatory effects of theophylline
The effects of theophylline on OVA allergen-induced his-
topathology in lung sections from treated mice are shown
in Fig. 3. The lung sections from OVA-challenged allergic
mice clearly show epithelial damage, luminal narrowing
due to airway wall edema and obstruction with excess
mucus which are typical of bronchial inflammation (Fig.
3b). Administration of chitosan or thiolated chitosan
nanoparticles to the sensitized and challenged mice did
not produce anti-inflammatory effects, however, theo-
phylline treatment produced a moderate reduction in
lung pathology. The mice treated with theophylline plus
TCNs, however, showed a considerable reduction in pul-
monary inflammation, decreased epithelial damage,
reduced goblet cell hyperplasia and fewer infiltrating
inflammatory cells in the interstitial and peribronchovas-
cular regions compared to the other groups (Fig. 3g).
Unstained lung sections were examined for expression of
mucin by staining with antibody against MUC5AC (Fig.
Experimental protocol used for ovalbumin-induced allergic asthma (A) and reduction of eosinophils in BAL fluid from theo- phylline (TPL)-treated mice (B) Figure 2
Experimental protocol used for ovalbumin-induced allergic asthma (A) and reduction of eosinophils in BAL fluid from theo-
phylline (TPL)-treated mice (B). BAL was performed and eosinophils were counted on day 22. The results of a representative 
experiment of two performed is shown. Cell counts were performed by different persons in a blinded fashion. CS denotes chi-
tosan. (**p < 0.01, *p < 0.07 relative to TPL-thioCS).
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4A). MUC5AC is the most prevalent mucin subtype in
mucus and is known to be specifically produced by airway
goblet cells [2,22]. OVA-allergic mice challenged with
OVA produce excess mucus in the airways and this hyper-
secretion is associated with an increased number of goblet
cells. Chitosan or thiolated chitosan did not reduce mucus
hypersecretion; but less immunoreactive MUC5AC was
observed in mice given theophylline treatment alone (Fig.
4A panelb), indicating that the drug was able to inhibit
goblet cell mucus production. The effect of theophylline
on the reduction of mucus hypersecretion was further
enhanced through delivery by TCNs (Fig. 4A paneld), sug-
gesting that TCNs with enhanced mucoadhesiveness
increased the absorption of theophylline and its anti-
inflammatory effects (Fig. 4B).
Allergic inflammation of the lung is characteristically
accompanied by infiltration of immune system cells such
as eosinophils which can increase the cytopathological
effects. A decrease in eosinophilia could reduce the
inflammatory effects of allergen challenge. To test this
hypothesis, unstained lung sections were examined for
apoptosis of inflammatory cells using the TUNEL assay.
No apoptotic (TUNEL-positive green fluorescent) cells
were observed in lungs from untreated mice or mice
treated with unmodified or thiolated chitosan nanoparti-
cles. Treatment with theophylline caused a modest
increase in number of apoptotic cells in the subepithelial
region beneath the airway basement membrane (Fig. 5,
panel c). Delivery of theophylline by TCNs, however, sig-
nificantly enhanced apoptosis (Fig. 5, panel e). These
results clearly demonstrate that theophylline is capable of
inducing apoptosis of lung cells and that its anti-inflam-
matory effects are enhanced when delivered with mucoad-
hesive TCNs.
Discussion
In this study we examined the anti-inflammatory effects of
the anti-asthma drug theophylline in ovalbumin-allergic
mice when delivered intranasally as a complex with TCNs.
Nasal drug delivery is considered to be a promising tech-
nique because of the large surface area in the nose, high
total blood flow, avoidance of first-pass metabolism,
quicker onset of pharmacological activity, porous
endothelial basement membranes, and ready accessibility
[23]. The nasal cavity presents an excellent route for chi-
tosan-based drug delivery systems because of the attrac-
tion of the particles to mucus. Chitosan has anti-
inflammatory and immunostimulatory activity, and is
able to increase transcellular and paracellular transport
across the mucosal epithelium [24]. Chitosan drug deliv-
ery systems employing nano/microspheres, liposomes,
emulsions and gels have been demonstrated to have good
bioadhesive characteristics for the nasal mucosa. Thus, it
is reasonable to postulate that bioavailability, adsorption
and residence time of drugs administered via the nasal
route would be increased by using a drug delivery system
such as chitosan nanoparticles with high mucoadhesion.
Histological analysis of mouse lung sections after theophylline treatment Figure 3
Histological analysis of mouse lung sections after theophylline treatment: (a) negative control, (b) untreated (OVA-challenged), 
(c) unmodified ('pure') chitosan nanoparticles, (d) Thiolated chitosan, (e) theophylline, (f) theophylline plus unmodified chitosan 
nanoparticles, (g) theophylline plus TCNs. On day 22, lungs were removed, sectioned and stained with hematoxylin/eosin. 
Examination of tissue sections was performed by different persons in a blinded fashion. The results of a representative experi-
ment of 3 slides for each section are shown.
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Various natural and synthetic polymers have been found
to have mucoadhesive properties. Their capability to
interact with glycoproteins in mucus is mainly based on
noncovalent ionic interactions, van-der Waal's forces and
hydrogen bonds [25]. The mucoadhesiveness of chitosan
is a result of electrostatic interaction between negatively
charged mucin and positively charged chitosan [15,26],
and the ionization of sialic acid residues is thought to be
responsible for the negative charge of mucin. This was
supported by our observation that both unmodified and
thiolated chitosan nanoparticles bound mucin I-S (con-
taining 12% sialic acid) more than mucin III (containing
1% sialic acid) (data not shown).
Unmodified chitosan nanoparticles have a higher zeta
potential than thiolated chitosan and therefore a greater
positive charge. This may account for the greater initial
adsorption of mucin by the unmodified particles at the 1
h time point (Fig. 1C). The reduced mucin adsorption on
thiolated chitosan is attributed to the diminished positive
charge of thiolated chitosan and subsequently decreased
electrostatic interaction with negatively charged mucin.
Expression of MUC5AC in unstained lung sections (A) Figure 4
Expression of MUC5AC in unstained lung sections (A): (a) untreated (OVA-challenged), (b) theophylline, (c) theophylline plus 
pure chitosan nanoparticles, (d) theophylline plus TCNs (top panel: nuclei stained with DAPI, bottom panel: FITC-labeled 
muc5AC) and semiquantitative analysis of muc5AC in unstained lung sections (B). The results of a representative experiment 
of two performed is shown. **p < 0.01, *p < 0.05 compared with TPL group.
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While unmodified chitosan nanoparticles reached
adsorption equilibrium at 1 h of incubation with mucin,
TCNs exhibited a steady increase in mucin adsorption up
to 12 hours. This enhanced mucoadhesiveness may be
attributed to the formation of disulfide bonds between
thiol groups on chitosan and cysteine-rich subdomains of
mucus glycoproteins [16,27]. Thus, TCNs are an excellent
candidate drug delivery platform for the mucus-rich bron-
chial epithelium [2,19,28]. Based on previous studies
showing that hydrogen bonds formed between the amino
groups of chitosan and the carbonyl groups of theophyl-
line, it was reasoned that theophylline first adsorbs onto
the chitosan nanoparticle surface then diffuses into the
interior of the particles during the incubation of theophyl-
line in the suspension of chitosan nanoparticles, [29],
where interaction with bioadhesive particles occurs in the
wet state [30].
Eosinophils are an important effector cell in the inflam-
matory response to allergens. Increased numbers of eosi-
(A) Apoptosis in unstained lung sections by TUNEL assay Figure 5
(A) Apoptosis in unstained lung sections by TUNEL assay: (a) untreated (OVA-challenged), (b) unmodified (pure) chitosan 
nanoparticles, (c) theophylline, (d) theophylline plus pure chitosan nanoparticles, (e) theophylline plus TCNs (top panel: nuclei 
stained with DAPI; bottom panel: apoptotic cells stained with FITC). (B) semiquantitative analysis of TUNEL positive cells. 
Examination of tissue sections was performed by different persons in a blinded fashion. The results of a representative experi-
ment of two performed is shown. **p < 0.01, *p < 0.05 compared with TPL.
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nophils are detectable in bronchial biopsy specimens and
in induced sputum from asthma patients [31]. Eosi-
nophils are known to produce and release cytotoxic pro-
teins and reactive oxygen species such as superoxide
which may contribute to epithelial damage and increased
bronchial hyperresponsiveness in asthmatic patients [4].
Recently, it has been recognized that theophylline can
inhibit inflammatory cells and have anti-inflammatory
effects on the airways of asthmatic patients [3,7,8,32].
Caramori and colleagues reported that eosinophil degran-
ulation and release of eosinophil basic proteins were
inhibited by high doses of theophylline [3]. In our work,
histological examination revealed that nasal delivery of
theophylline inhibited the infiltration of inflammatory
cells beneath the epithelium and reduced epithelial dam-
age in OVA-allergic mice. The reduction in eosinophils in
BAL fluid was greater when theophylline was delivered by
TCNs than by unmodified chitosan nanoparticles. These
results clearly demonstrate that thiolation enhances the
capacity of chitosan nanoparticles to effectively deliver
theophylline to bronchial epithelium. It is likely that the
enhanced anti-inflammatory effects of theophylline deliv-
ered by TCNs result from their increased mucoadhesive-
ness.
It has been suggested that apoptosis or programmed cell
death of inflammatory cells may be an effective therapeu-
tic strategy for allergic asthma. Ohta et al. reported that
theophylline induced apoptosis in eosinophils and lym-
phocytes by means of elevation of intracellular cAMP
[32]. Our results here showed that theophylline delivered
by TCNs markedly induced apoptosis of inflammatory
cells, presumably eosinophils and lymphocytes. It is also
possible that theophylline reduced the number of eosi-
nophils in BAL fluid in part by inhibiting their migration,
although induced apoptosis of activated eosinophils at
the subepithelial region beneath the basement membrane
of the airway appears to be its primary activity. Induction
of apoptosis of activated inflammatory cells by theophyl-
line may be a beneficial strategy for treating allergic
inflammation.
Mucus has an important role in host defense of upper and
lower respiratory tracts, but represents an important cause
of airway obstruction in asthma when secreted in excess
[33]. Mucus hypersecretion can be an important cause of
morbidity and mortality in patients with respiratory tract
diseases such as asthma [34]. Muc5AC is the most com-
mon mucin secreted by goblet cells and it is the major gel-
forming mucin in airway secretions. Lung sections stained
with antibody against Muc5AC showed that mucus hyper-
secretion was remarkably inhibited by theophylline when
delivered with TCNs, further supporting the observation
that TCNs enhance the anti-inflammatory effect of theo-
phylline. The mechanism underlying the increased drug
delivery efficacy of TCNs is unclear. However, the most
probable explanation is that the thiol groups provide chi-
tosan with enhanced mucoadhesiveness and cell permea-
bility via the paracellular and transcellular routes as
suggested previously [30].
In summary, theophylline delivered intranasally as a com-
plex with thiolated chitosan affords protection against the
allergic lung inflammation induced by OVA sensitization
and challenge in mice. The anti-inflammatory effects of
theophylline were markedly enhanced when the drug was
delivered by TCNs compared to unmodified chitosan or
theophylline alone. The increased mucoadhesiveness of
TCNs provides an effective mucosal drug delivery plat-
form and a novel strategy to enhance the beneficial
actions of theophylline in treating allergic inflammation.
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